DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Balar AV, Castellano D, O'Donnell PH. et al.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Lancet Oncol 2017;
18: 1483-1492
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.